Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

BridgeBio Pharma Announced That Encaleret Showed Parathyroid Hormone-independent Normalization Of Blood And Urine Calcium In Post-surgical Hypoparathyroidism In Phase 2 Trial

Author: Benzinga Newsdesk | September 07, 2025 12:23pm

80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline.
Encaleret was well-tolerated with no serious adverse events reported over the study period.
Based on these findings, BridgeBio intends to initiate a registrational clinical study of encaleret, an orally-administered investigational therapy, in chronic hypoparathyroidism in 2026

Posted In: BBIO